• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Circulating monocytes in contributing to myocardial involvement of systemic sclerosis

Research Project

Project/Area Number 20K08812
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 54020:Connective tissue disease and allergy-related
Research InstitutionNippon Medical School

Principal Investigator

Kuwana Masataka  日本医科大学, 大学院医学研究科, 大学院教授 (50245479)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords全身性強皮症 / バイオインフォマティクス / 心筋 / 強皮症 / 心筋炎 / 単球 / マクロファージ
Outline of Research at the Start

全身性強皮症(SSc)の病態として血管障害→慢性炎症→線維化のプロセスが示されている。申請者はこれまでSScの病態プロセスをつなぐmajor playerとして単球マクロファージに着目し、患者検体やモデルマウスを用いてその役割を実証してきた。本研究では、これまでの成果から「継続的な心筋の虚血・再潅流傷害に対して骨髄から動員された心筋指向性単球が心筋にリクルートされ、線維化を促進することでSScに特徴的な心筋病変を形成する」という仮説をたて、in vitro/in vivo実験系を用いて検証する。本研究は学術的独自性が高く、その成果は心病変のバイオマーカー、新たな治療法の開発に資する。

Outline of Final Research Achievements

The heart involvement in systemic sclerosis (SSc) is a poor prognostic factor, although the detailed pathogenesis remains unclear. We conducted transcriptomic analysis of myocardial tissue samples obtained by endomyocardial biopsy from SSc patients with primary heart involvement. Compared to the control group (dilated cardiomyopathy), the SSc myocardium showed activation of pathways related to myocardial energy metabolism, such as fatty acid beta-oxidation and the citric acid cycle, and upstream regulators including NUPR1 and IL-1β were predicted to be activated, leading to dysregulation of microtubules and cytoskeleton of the heart. Estimation of immune cell population did not show any significant differences in the number of specific cell types or oligoclonality compared with the control. These findings suggests that SSc myocardium have a distinct molecular pathogenesis compared to dilated cardiomyopathy.

Academic Significance and Societal Importance of the Research Achievements

本研究はSSc患者心筋を用いた初めてのトランスクリプトーム解析である。症例数が少ない、対照が健常心筋ではなく拡張型心筋症患者の心筋であるなど制約があるものの、仮説なしの網羅的解析により病態と関連するパスウェイや上流制御因子が同定された学術的意義は大きい。本研究成果は難治性病態の解明に役立つとともに、新たに同定された治療標的に対する新規治療薬の開発につながる可能性を秘めている。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (17 results)

All 2022 2021 2020

All Journal Article (12 results) (of which Int'l Joint Research: 4 results,  Peer Reviewed: 12 results,  Open Access: 4 results) Presentation (5 results) (of which Int'l Joint Research: 5 results,  Invited: 1 results)

  • [Journal Article] Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis2022

    • Author(s)
      Shirai Y, Kawami N, Iwakiri K, Kuwana M
    • Journal Title

      J Scleroderma Relat Disord

      Volume: 7 Issue: 1 Pages: 57-61

    • DOI

      10.1177/23971983211021747

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan2022

    • Author(s)
      Isomura Y, Shirai Y, Kuwana M
    • Journal Title

      Rheumatology (Oxford)

      Volume: - Issue: 11 Pages: 4491-4496

    • DOI

      10.1093/rheumatology/keac136

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Primary systemic sclerosis heart involvement: a systematic literature review and preliminary consensus-based WSF/HFA definition2021

    • Author(s)
      Bruni C, Kuwana M. (35人中27番目)
    • Journal Title

      J. Scleroderma Relet. Disord

      Volume: 7 Issue: 1 Pages: 24-32

    • DOI

      10.1177/23971983211053246

    • Related Report
      2022 Annual Research Report 2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: results from a multicentre prospective cohort in Japan.2021

    • Author(s)
      Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, and Takehara K
    • Journal Title

      Mod. Rheumatol

      Volume: 31(2) Issue: 2 Pages: 386-393

    • DOI

      10.1080/14397595.2020.1784548

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Updates on genetics in systemic sclerosis2021

    • Author(s)
      Ota Y, and Kuwana M
    • Journal Title

      Inflamm. Regen

      Volume: 4 Issue: 1 Pages: 17-17

    • DOI

      10.1186/s41232-021-00167-6

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] A randomized, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale2021

    • Author(s)
      Spiera R, Khanna D, Kuwana M, Furst DE, Frech TM, Hummers L, Stevens W, Matucci-Cerinic M, Baron M, Distler O, Dgetluck N, Bloom BJ, Dinh Q, White B, and Denton CP
    • Journal Title

      Clin. Exp. Rheumatol

      Volume: 131 Pages: 124-133

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Clinical relevance of the serial measurement of Krebs von den Lungen-6 levels in patients with systemic sclerosis-associated interstitial lung disease2021

    • Author(s)
      Shirai Y, Fukue R, Kaneko Y, Kuwana M
    • Journal Title

      Diagnostics

      Volume: 11 Issue: 11 Pages: 2007-2007

    • DOI

      10.3390/diagnostics11112007

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score.2021

    • Author(s)
      Kuwana M, Allanore Y, Denton CP, Distler JHW, Steen VD, Khanna D, Matucci-Cerinic M, Mayes MD, Volkmann ER, Miede C, Gahlemann M, Quaresma Lic M, Alves M, and Distler O
    • Journal Title

      Arthritis Rheumatol

      Volume: 74 Issue: 3 Pages: 518-526

    • DOI

      10.1002/art.41965

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Therapeutic approaches to systemic sclerosis: Recent approvals and future candidate therapies2021

    • Author(s)
      Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, and Khanna D
    • Journal Title

      Clin. Rev. Allergy Immunol

      Volume: - Issue: 3 Pages: 239-261

    • DOI

      10.1007/s12016-021-08891-0

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Outcomes in patients with systemic sclerosis undergoing early versus delayed intervention with potential disease-modifying therapies2021

    • Author(s)
      Yomono K and Kuwana M
    • Journal Title

      Rheumatology (Oxford)

      Volume: - Issue: 9 Pages: 3677-3685

    • DOI

      10.1093/rheumatology/keab931

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-interstitial lung disease2021

    • Author(s)
      Nawata T, Shirai Y, Suzuki M, and Kuwana M
    • Journal Title

      Rheumatology (Oxford)

      Volume: 60(1) Issue: 1 Pages: 250-255

    • DOI

      10.1093/rheumatology/keaa322

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management2020

    • Author(s)
      Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov N, De Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg T, Kuwana M, Lee EB, Li, Pillai S, Wang Y, Zeng X, and Taliani G
    • Journal Title

      Ann. Rheum. Dis

      Volume: 79(6) Issue: 6 Pages: 724-726

    • DOI

      10.1136/annrheumdis-2020-217407

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Presentation] Management of pulmonary arterial hypertension and interstitial lung disease associated with systemic sclerosis2021

    • Author(s)
      Kuwana M
    • Organizer
      23st Asia Pacific League of Associations for Rheumatology Congress. APLAR2021
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] Outcomes of Dose-Reduction or Discontinuation of Tocilizumab in Patients with Early Diffuse Cutaneous Systemic Sclerosis2021

    • Author(s)
      Isomura Y, Yamasaki Y, Shirai Y, Kuwana M
    • Organizer
      Annual European Congress of Rheumatology EULAR2021
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Presentation] Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial2021

    • Author(s)
      Assassi S, Christopher P Denton, Cutolo M, Tracy R Luckhardt, Diefenbach C, Ittrich C, Alves M, Kuwana M on behalf of the SENSCIS trial investigators
    • Organizer
      ACR Convergence2021
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Presentation] Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis.2021

    • Author(s)
      Yomono K, and Kuwana M
    • Organizer
      ACR Convergence2021
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Presentation] Effects of Nintedanib on Patient-Reported Outcomes in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Sub-Analysis of INBUILD2020

    • Author(s)
      Kuwana M, Inoue Y, Inase N, Makino S, Takizawa A, Takenouchi K, Rohr K, Schlenker-Herceg R, Takeuchi T
    • Organizer
      APLAR2020
    • Related Report
      2020 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi